Leif Jorgensen
Overview
Explore the profile of Leif Jorgensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lisspers K, Larsson K, Johansson G, Janson C, Costa-Scharplatz M, Gruenberger J, et al.
Int J Chron Obstruct Pulmon Dis
. 2018 Feb;
13:275-285.
PMID: 29391785
Background: We assessed direct and indirect costs associated with COPD in Sweden and examined how these costs vary across time, age, and disease stage in a cohort of patients with...
12.
Rockberg J, Amelio J, Taylor A, Jorgensen L, Ragnhammar P, Hansson J
Int J Cancer
. 2016 Aug;
139(12):2722-2729.
PMID: 27563839
Cutaneous malignant melanoma (CMM) incidence is increasing globally, making a thorough understanding of the disease and its outcomes essential for optimizing care even more urgent. In this population-based, retrospective study,...
13.
Lind M, Matsson P, Linder R, Svenningsson I, Jorgensen L, Ploug U, et al.
Diabetes Ther
. 2016 May;
7(2):321-33.
PMID: 27216947
Introduction: The aim of the present study was to use real-world data from Swedish primary-care and national registries to understand clinical outcomes in patients with Type 2 diabetes (T2D) treated...
14.
Lazarinis N, Jorgensen L, Ekstrom T, Bjermer L, Dahlen B, Pullerits T, et al.
Thorax
. 2013 Oct;
69(2):130-6.
PMID: 24092567
Background: In mild asthma exercise-induced bronchoconstriction (EIB) is usually treated with inhaled short-acting β2 agonists (SABAs) on demand. Objective: The hypothesis was that a combination of budesonide and formoterol on...
15.
Eriksson L, Hallerback T, Jorgensen L, Carlborg A
Ther Adv Psychopharmacol
. 2013 Aug;
2(6):217-26.
PMID: 23983980
Quetiapine fumarate, a first-line treatment for schizophrenia, exists in two formulations: extended release (XR) and immediate release (IR). This naturalistic, noninterventional study evaluated use of quetiapine XR/IR among in-patients with...
16.
Bauer M, DellOsso L, Kasper S, Pitchot W, Vansvik E, Kohler J, et al.
J Affect Disord
. 2013 Jul;
151(1):209-19.
PMID: 23810357
Background: Patients with treatment-resistant major depressive disorder (MDD) remain a common clinical challenge. Methods: This 6-week, randomised, open-label, rater-blinded trial evaluated once-daily extended-release quetiapine fumarate (quetiapine XR; 300 mg/day) as...
17.
Janson C, Larsson K, Lisspers K, Stallberg B, Stratelis G, Goike H, et al.
BMJ
. 2013 May;
346:f3306.
PMID: 23719639
Objective: To investigate the occurrence of pneumonia and pneumonia related events in patients with chronic obstructive pulmonary disease (COPD) treated with two different fixed combinations of inhaled corticosteroid/long acting β2...
18.
Emborg C, Hallerback T, Jorgensen L, Carlborg A
Hum Psychopharmacol
. 2012 Sep;
27(5):492-8.
PMID: 22996616
Objectives: The atypical antipsychotic quetiapine is a first-line treatment for schizophrenia. This non-interventional study (NCT01212575) evaluated the clinical use of its two formulations, extended release (XR) and immediate release (IR),...
19.
Fismen S, Ingvarsson G, Moseng D, Dufour D, Jorgensen L
APMIS
. 2012 May;
120(6):433-40.
PMID: 22583355
We report the results of a re-examination of a series of 57 biopsies from 50 patients with the clinical diagnosis of hidradenitis suppurativa, submitted to the Department of Pathology at...
20.
Thorn J, Tilling B, Lisspers K, Jorgensen L, Stenling A, Stratelis G
Prim Care Respir J
. 2012 Jan;
21(2):159-66.
PMID: 22270480
Background: The importance of identifying chronic obstructive pulmonary disease (COPD) at an early stage is recognised. Improved and easily accessible identification of individuals at risk of COPD in primary care...